Yes, and another rival going down the 'dystrophin' route.
...and targeting a small subset of DMD boys (13%)...same as Sarepta's Exondys51.
PepGen stated goal is to raise 'wild-type dystrophin' to between 10-12%.
BUT we know from Sraepta's results that:
...the additional dystrophin does not stop inflammation...in fact it may increase 'matrix deposition' / fibrosis as the body responds to the new 'wild-type' dystrophin.
Biggest take away from me is the $113m CR...lots of Biotech $$$ looking for projects.
Big week ahead folks!
.
Where others have failed will Atl1102 succeed ?, page-741
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.6¢ |
Change
0.003(4.11%) |
Mkt cap ! $67.61M | |||
| Open | High | Low | Value | Volume |
| 7.3¢ | 7.6¢ | 7.3¢ | $28.43K | 378.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 155995 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 92207 | 2 |
View Market Depth
| Last trade - 14.38pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.6¢ |
Change
0.003 ( 5.56 %) |
||||
| Open | High | Low | Volume | ||
| 7.5¢ | 7.6¢ | 7.4¢ | 32400 | ||
| Last updated 14.37pm 02/05/2024 ? | |||||
| PER (ASX) Chart |